Role of somatostatin in the incidence of post – ERCP pancreatitis

Assessment the role of somatostatin and indomethacin versus only indomethacin in the incidence of post – ERCP pancreatitis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20080921001264N11

Enrollment

360

Registered

2020-06-29

Start date

2018-03-21

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatitis. Acute pancreatitis, unspecified

Interventions

Intervention 1: Intervention group: somatostatin plus indometacin. Somatostatin 250 µg bolus for 1-2 minutes pre-ERCP Long-term infusion of somatostatin 500µg, started during ERCP and lasted for two h

Eligibility

Sex/Gender

All

Age

18 Years to 95 Years

Inclusion criteria

Inclusion criteria: All patients with biliary tract problems who refer to 5 Azar Hospital in gorgan to perform ERCP diagnostic-therapeutic method from the beginning of April 2017.

Exclusion criteria

Exclusion criteria: Previous history of sphincterotomy history of chronic pancreatitis acute pancreatitis when visiting Allergy to somatostatin or NSAIDS

Design outcomes

Primary

Measure	Time frame
Pancreatitis. Timepoint: 2 and 18 hours. Method of measurement: serum amylase.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Norouzi

Gorgan University of Medical Sciences

norouzi54@gmail.com+98 17 3242 4103

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 12, 2026